Posted by Site Administrator on March 1, 2013
Because of the relentless effects of ALS, a diverse group of ALS voices — patients, families, organizations and the community — came together to speak about their experiences with ALS and to urge the FDA to work with them to overcome some of the obstacles faced in ALS research, clinical trials and standards of care.
Categories: Clinical Trials, Research News, Treatments
| 
Tags: a diverse group of ALS voices — patients, ALS, ALS clinical trials, ALS community, ALS cure, ALS medical care, ALS research, ALS research funding, ALS survivor Robert Anderson, ALS treatments, amyotrophic lateral sclerosis, Because of the relentless effects of ALS, Bob Stehlin, clinical trials and standards of care., Dr. Jonathan Glass, families, fast-track trials ALS, FDA, FDA ALS, Food and Drug Administration, Lou Gehrig's disease, MDA Senior Vice President of Advocacy Annie Kennedy, MDA/ALS Center of Hope in Philadelphia, MDA/ALS Clinic at Methodist Neurological Institute in Houston, Muscular Dystrophy Association MDA, organizations and the community — came together to speak about their experiences with ALS and to urge the FDA to work with them to overcome some of the obstacles faced in ALS research, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, Sara M. Feldman, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Stan Appel, Steven M. Derks
| 
No comments
Posted by Site Administrator on November 10, 2012
“Patients who suffer from this devastating disease are in critical need of a novel therapy that addresses the functional deficits that limit their activities of daily living,” stated Jeremy M. Shefner, MD, PhD, Professor and Chair of the Department of Neurology at the Upstate Medical University at the State University of New York and Principal Investigator of BENEFIT-ALS. “If successful, this novel mechanism therapy could improve the lives of many patients living with ALS.”
Categories: Clinical Trials, Research News, Treatments
| Tags: ALS, ALS community, ALS medical care, ALS research, ALS treatments, amyotrophic lateral sclerosis, BENEFIT-ALS (Blinded Evaluation of Neuromusclar Effects and Functional Improvement with Tirasemtiv in ALS), Bob Stehlin, CK-2017357, CY 4026, Cytokinetics Incorporated, Department of Neurology at the Upstate Medical University at the State University of New York, FDA ALS, Jeremy M. Shefner MD PhD, Lou Gehrig's disease, Phase II clinical trial, Phase IIb, RASCALS Foundation, riluzole, Robert A. Stehlin Campaign for ALS, skeletal muscle troponin complex, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, State University of New York, Tirasemtiv
| No comments
Posted by Site Administrator on October 4, 2012
South San Francisco biotechnology company Cytokinetics announced Sept. 10, 2012, that it plans to conduct a new phase 2b clinical trial of its oral drug tirasemtiv (formerly CK-2017357) in people with amyotrophic lateral sclerosis (ALS). The trial is set to launch later this year.
Categories: Clinical Trials, Research News, Treatments
| Tags: ALS, ALS community, ALS research, ALS treatments, amyotrophic lateral sclerosis, Andrew A. Wolff, CK-2017357, Cytokinetics, FDA ALS, Lou Gehrig's disease, PALS, phase 2b clinical trial tirasemtiv, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis, Tirasemtiv
| No comments
